Fasting-mimicking diet potentiates anti-tumor effects of CDK4/6 inhibitors against breast cancer by suppressing NRAS- and IGF1-mediated mTORC1 signaling
Drug Resistance Updates · 2025-01 · 78 · 101182
DOI: 10.1016/j.drup.2024.101182 ↗Kurz gefasst
Editorial in der Zeitschrift Drug Resistance Updates, 2025-01. Verfasst von Sebastian Brandhorst und 1 weiteren Autor:innen. Beteiligte Einrichtung: Longevity Institute, Davis School of Gerontology, University of Southern California, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Fasting. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Abstract (Originalsprache)
Fasting-mimicking diet (FMD) cycles, defined as 3-5 day periods of a calorie-restricted, low-protein, low-carbohydrate, and high-fat diet, have emerged as a dietary approach to delay cancer initiation and progression in both autograft and xenograft mouse models and as a safe and feasible approach to decrease risk factors for cancer and other age-related pathologies in humans. A substantial number of pre-clinical studies focused on various tumor types have shown that fasting/FMDs can potentiate the efficacy of various standard-of-care cancer therapies but also modulate the immune system to promote a T cell-dependent attack of tumor cells. Importantly, combining drug treatment with fasting/FMDs can overcome acquired drug resistance which frequently emerges and reduces long-term treatment benefits. However, the mechanisms by which the FMD reverts resistance to CDK4/6i remain poorly understood. Here, Li and colleagues provide evidence that FMD cycles act as a wild card to reduce the activity of a signaling network that includes IGF-1, RAS, AKT, and mTOR-S6K to delay cancer progression and reverse the acquisition of drug resistance. These findings expand the mechanistic understanding of the FMD-mediated increase in drug efficacy and provide further evidence to support trials combining hormone therapy, CDK4/6 inhibitors, and FMD in breast cancer treatment. These new results on FMD cycles add an optimistic outlook to extend the efficacy of standard-of-care drugs that eventually become ineffective because of acquired resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Longevity Institute, Davis School of Gerontology, University of Southern California, USA.
- Longevity Institute, Davis School of Gerontology, University of Southern California, USA. Electronic address: vlongo@usc.edu.
Zitieren
APA
Brandhorst, S., & Longo, V. D. (2025). Fasting-mimicking diet potentiates anti-tumor effects of CDK4/6 inhibitors against breast cancer by suppressing NRAS- and IGF1-mediated mTORC1 signaling. Drug Resistance Updates, 78, 101182. https://doi.org/10.1016/j.drup.2024.101182
Vancouver
Brandhorst S, Longo VD. Fasting-mimicking diet potentiates anti-tumor effects of CDK4/6 inhibitors against breast cancer by suppressing NRAS- and IGF1-mediated mTORC1 signaling. Drug Resistance Updates. 2025;78:101182. doi:10.1016/j.drup.2024.101182
BibTeX
@article{Brandhorst2025,
author = {Brandhorst, Sebastian and Longo, Valter D},
title = {Fasting-mimicking diet potentiates anti-tumor effects of CDK4/6 inhibitors against breast cancer by suppressing NRAS- and IGF1-mediated mTORC1 signaling},
journal = {Drug Resistance Updates},
year = {2025},
volume = {78},
pages = {101182},
doi = {10.1016/j.drup.2024.101182}
}
EUVIMED